N/A N=35 Ultrasound-guided Peripheral IJ Study
IV Access
Primary: Number of Participants With Successful Cannulation of the Internal Jugular Vein — 34 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=95 AccuCath™ Intravenous (IV) Device Used by Vascular Access Team (VAT)
Vascular Access Complication
Primary: Percentage of Participants With Successfully Inserted Peripheral IV Catheter Placement on First Attempt — 85.3 percentage of participants
N/A N=217 Central Venous Access Study
Central Line Catheters
Primary: Adherence to Clinical Guidelines for Catheter Interventions and Management — 12; 0; 0; 11 # of catheter-related incidents
N/A N=243 Optical Detection of Intravenous Infiltration:A Pilot Study
Infiltration of Peripheral IV Therapy
Primary: Time Infiltration Detected by Nurse — 29.8; 32.3 hours
Phase 4 N=1,054 Oral Versus Intravenous Antibiotics for Bone and Joint Infections (OVIVA B&J)
Bone Infection · Joint Infection
Primary: The Frequency of Definite Failure of Infection Treatment. — 67; 74 Participants
N/A N=22 Intraosseous Access in the Emergency Department for Patients With Failed Attempts at Intravenous Access: A Randomized Trial Examining Resource Utilization and Patient Satisfaction
Difficult Peripheral IV Access
Primary: Time to Successful Placement of a Functioning USGIV/IO — 163.7; 67.3 seconds
N/A N=220 Comparison of AccuCath IV Catheter and Conventional IV Catheter in Interventional Radiology
Vascular Access Complications
Primary: First Attempt Success Rate With Peripheral IV (PIV) Catheter Placement — 84; 90 Participants
N/A N=350 Peripheral Intravenous Catheter Securement With Tissue Adhesive
Vascular Access Devices
Primary: IV Catheter Survival — 66; 55 Participants
N/A N=152 Complications Associated With Central Venous Access in the NSICU: PICC vs CVC
PICC · Central Venous Catheter · Central Line
Primary: Participants With Complications With Central Access Including Insertion — 14; 10 Participants — p=0.271
N/A N=127 Continuous Intraosseous Vascular Access Over 48 Hours
Intraosseous Vascular Access
Primary: Serious Complications From Intraosseous (IO) Access — 0; 0; 0; 0 Participants
Phase 3 N=64 IGIV Study for Chronic ITP Patients Ages 3-70
Idiopathic Thrombocytopenic Purpura
Primary: Response Rate — 81.3 percentage of responders
N/A N=182 Intraosseous Versus Intravenous Vascular Access During Cardiac Arrest
Cardiac Arrest
Primary: First Attempt Success Rate Between the Tibial IO, Humeral IO, and Peripheral IV. — 26; 17; 58 Participants
N/A N=48 Intervention for Victimized Youth
Victimization
Primary: Change in Social-emotional Distress — 1.09; 1.07; 0.97; 1.00 mean item score on a scale — p=0.646
N/A N=99 ivWatch Sensor: Device Validation for Infiltrated Tissues
Infiltration of Peripheral IV Therapy
Primary: Red Notification Sensitivity to Infiltrated Tissues — 99.0; 99.0 percentage of infiltrations detected
N/A N=248 AccuCath Guidewire Intravenous (IV) Device Versus Conventional IV Catheter In General Nursing Use
Vascular Access Complication
Primary: First Attempt Success Rate With Peripheral IV Catheter Placement — 89; 47 percentage of participants — p=<0.0001
Phase 4 N=30 Vapocoolant Spray Used Prior to Intravenous (IV) Insertions
Pain
Primary: Pain Scale Using Visual Analog Scale — 1.13; 1.60 score on a scale
Phase 4 N=58 Intravenous Fluids in Benign Headaches Trial
Headache
Primary: Reduction in Pain Scores at 60 Minutes — 48.7; 48.3 reduction in visual analog pain score
Phase 4 N=57 IV Iron Safety: Evaluation of Iron Species in Healthy Subjects
Anemia
Primary: Non-transferrin Bound Iron — 56230; 61250 ppb x hours
Phase 3 N=159 IVPCA in the Management of Pain Following Major Intracranial Surgery
Intracranial Surgery
Primary: Hourly Pain Scores — 2.5; 3.6; 3.7; 5.2 units on a scale
N/A N=71 ivWatch Model 400: Device Validation for Infiltrated Tissues
Infiltration of Peripheral IV Therapy
Primary: Red Notification Sensitivity to Infiltrated Tissues — 96.4 percentage of infiltrations
N/A N=104 IV Insulin Protocol in Diabetes and Renal Transplantation
Kidney Transplantation · Diabetes · Hyperglycemia
Primary: Delayed Graft Function — 8; 12 participants
Phase 2 N=30 Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia
Biliary Atresia
Primary: Feasibility of IVIG Treatment — 23 Participants
N/A N=330 IN.PACT™ AV Access IDE Study
Arteriovenous Fistula Stenosis · Arteriovenous Fistula Occlusion · Arteriovenous Fistula
Primary: Target Lesion Primary Patency Rate Through 6 Months — 125; 88 Participants — p=<0.001
Phase 4 N=30 IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab
Diabetic Macular Edema
Primary: Reduction in Macular Edema — 15; 8; 4 Participants
N/A N=50 Ultrasound-Guided Peripheral Venous Access Using AccuCath
Intravenous Access
Primary: First Attempt Success Rate — 17; 11 Participants
Phase 1 N=18 EASI Access II --- Follow-up Study to the EASI Access Trial
Disaster Medicine · Difficult Intravenous Access · Dehydration
Primary: Number of Participants With Successfully Placed EASI Lines — 18 Participants
Phase 3 N=1,382 DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
Post Menopausal Osteoporosis
Primary: Relative Percent Change From Baseline in Mean Bone Mineral Density (BMD) of Lumbar Spine (L2-L4) at 12 Months — 3.8199; 5.0872; 4.8188 Percent Change — p=<0.001
Phase 3 N=117 Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Primary: Comparison of the Responder Rates Between Two Treatment Groups in the Efficacy Period — 54.2; 20.7 percentage of responders — p=<0.001
N/A N=5 Proximal Humerus Site for Anesthesia
Intraosseous Vascular Access
Primary: Intraosseous Infusion Flow Rate — 2433.33 mL / hour
Phase 4 N=19 Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial
Atrial Fibrillation and Flutter
Primary: Heart Rate Control — 8; 4 Participants